CareDx Stock (NASDAQ:CDNA), Trade Ideas

CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADMP

AFRM

AMSC

APVO

AURC

AZPN

CACC

CDLX

CDNA

CERE

CMBM

COCO

CRKN

CVGI

DBVT

DRVN

ERIE

EXAS

FEMY

FRSH

FTDR

GNRC

HMAC

IDAI

IMXI

LFUS

LIDR

LTCH

LUMN

MEDS

MGAM

The Marygold Companies, Inc. Common Stock

MGLD

MLNK

MSGM

NVRO

PAYC

RDWR

ROCK

ROVR

SEDG

SHYF

SPCE

TEVA

TRVG

WAVD

WRNT

XPEV

Gainers


	WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract.


Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

CIGI

NMIH

POWL

RGEN

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session.

Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical  And Other Big Stocks Moving Higher On Wednesday

AIRS

ETSY

HSAI

MESO

RDFN

ROKU

SSTK

TNDM

WDFC

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

WD-40, Shutterstock And Other Big Stocks Moving Higher On Tuesday

CareDx Inc

CANADIAN TIRE LTD A by Canadian Tire Corp. Ltd.

Canadian Tire Corp Ltd

Stephens &amp; Co. analyst Mason Carrico reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Overweight and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

Stephens & Co. Reiterates Overweight on CareDx, Maintains $15 Price Target

Management

CareDx Appoints John W. Hanna As Its New President And CEO, And Member Of Board Of Directors, Effective April 15, 2024

Guidance

CareDx Expects 2024 Revenue Of $260M-$274M, Est $260.618M

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
CareDx beat estimated earnings by 37.0%, reporting an EPS of $-0.17 versus an estimate of $-0.27.
Revenue was down $16.82 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.21 which was followed by a 14.000000000000002% increase in the share price the next day.
Here's a look at CareDx's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.39</td>
<td>-0.31</td>
<td>-0.11</td>
<td>-0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.18</td>
<td>-0.11</td>
<td>-0.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>53.14M</td>
<td>61.76M</td>
<td>80.70M</td>
<td>81.66M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>67.19M</td>
<td>70.30M</td>
<td>77.26M</td>
<td>82.38M</td>
</tr>
</tbody>
</table>

To track all earnings releases for CareDx <a href="https://www.benzinga.com/quote/CDNA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: CareDx Q4 Earnings

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.27) by 37.04 percent. The company reported quarterly sales of $65.57 million which beat the analyst consensus estimate of $63.66 million by 3.01 percent. This is a 20.41 percent decrease over sales of $82.38 million the same period last year.

Earnings Beats

CareDx Q4 2023 Adj EPS $(0.17) Beats $(0.27) Estimate, Sales $65.57M Beat $63.66M Estimate

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement.
Analysts estimate that CareDx will report an earnings per share (EPS) of $-0.27. 
CareDx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.21, which was followed by a 13.9% increase in the share price the next day.
Here's a look at CareDx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.39</td>
<td>-0.31</td>
<td>-0.11</td>
<td>-0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.18</td>
<td>-0.11</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>14.000000000000002%</td>
<td>-11.0%</td>
<td>-3.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709056924_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of CareDx were trading at $8.92 as of February 26. Over the last 52-week period, shares are down 41.31%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CDNA/earnings">To track all earnings releases for CareDx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For CareDx

<a href="https://seekingalpha.com/news/4059239-caredx-drops-after-jury-votes-in-favor-of-natera-in-patent-fight?utm_source=bloomberg_st&amp;utm_medium=referral&amp;feed_item_type=news" title="https://seekingalpha.com/news/4059239-caredx-drops-after-jury-votes-in-favor-of-natera-in-patent-fight?utm_source=bloomberg_st&amp;utm_medium=referral&amp;feed_item_type=news">https://seekingalpha.com/news/4059239-caredx-drops-after-jury-votes-in-favor-of-natera-in-patent-fight?utm_source=bloomberg_st&amp;utm_medium=referral&amp;feed_item_type=news</a>

Legal

NTRA

'CareDX Drops After Jury Votes In Favor Of Natera In Patent Fight' - Seeking Alpha

Rumors

Watching CareDx; Hearing Patent Case Lost To Natera

Preliminary cash, cash equivalents, and marketable securities were approximately&nbsp;$235 million&nbsp;as of December 31, 2023.

CareDx Expects Q4 Preliminary Revenue Of $65M-$66M, Down Approximately 3% Q/Q; Est. $61.71M

Preliminary revenue for the full year ended December 31, 2023, is expected to be between&nbsp;$279 million&nbsp;and&nbsp;$280 million, a decrease of approximately&nbsp;13%&nbsp;compared with&nbsp;$321.8 million&nbsp;in 2022, primarily driven by the impact of the Medicare Billing Article on Testing Services revenue.&nbsp;

CareDx Expects Full Year 2023 Revenue Of $279M-$280M, Which Is Above The High End Of Guidance; Est $276.43M

Natera successfully achieves key objective for trial set to begin on Jan. 22nd
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=53869256&amp;newsitemid=20231211868061&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=81d25063e34eb574b9c47ced7f0335d5">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx's motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx.
The Court has ruled that two of the patents asserted by Natera against CareDx will proceed to trial. The trial will commence on January 22, 2024.
The company stated: "We are gratified that the Court has issued a decision that provides a clear path to trial as we work to protect our significant investments in innovation from unlawful infringement."
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.natera.com%2Fcompany%2Fnews%2Fsupreme-court-denies-caredx-request-for-appeal-in-patent-case-with-natera%2F&amp;esheet=53869256&amp;newsitemid=20231211868061&amp;lan=en-US&amp;anchor=As+previously+disclosed&amp;index=2&amp;md5=9c9f324d21455f7556d07f5b9ea5093f">As previously disclosed</a>, Natera successfully invalidated all three of CareDx's patents that were asserted against Natera in a related case.

Delaware Court Denies CareDx's Motion For Summary Judgment On Two Natera Patents; Achieves Key Objective For Trial Set To Begin On Jan. 22nd

Stephens &amp; Co. analyst Mason Carrico upgrades CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) from Equal-Weight to Overweight and announces $10 price target.

Upgrades

Stephens & Co. Upgrades CareDx to Overweight, Announces $10 Price Target

WIIM

CareDX shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY23 revenue guidance above estimates.

<h3>Gainers</h3>
<ul>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares increased by 72.0% to $0.39 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) shares increased by 29.8% to $2.7. The company's market cap stands at $22.2 million. The company's, Q3 earnings came out today. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 20.0% to $0.09. The company's market cap stands at $4.0 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) stock increased by 19.9% to $7.59. The company's market cap stands at $411.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock increased by 17.27% to $1.29. The market value of their outstanding shares is at $7.4 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares moved upwards by 14.82% to $0.11. The market value of their outstanding shares is at $26.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares decreased by 51.6% to $0.59 during Thursday's pre-market session. The company's market cap stands at $59.6 million. </li>
<li>Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) shares decreased by 46.95% to $1.13. The company's market cap stands at $105.2 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 23.31% to $0.35. The company's market cap stands at $27.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) shares decreased by 16.89% to $14.96. The company's market cap stands at $1.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares declined by 16.73% to $0.6. The company's market cap stands at $14.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock declined by 16.21% to $0.77. The company's market cap stands at $3.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ASRT

ATRA

Intelligent Bio Solutions Inc. - Common Stock

INBS

KZIA

LIPO

OTRK

TCRT

ZVSA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

CareDX Sees FY23 Revenue $274M-$278M Vs $255.42M Est.

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
CareDx beat estimated earnings by 53.85%, reporting an EPS of $-0.18 versus an estimate of $-0.39.
Revenue was down $12.17 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.13 which was followed by a 11.23% drop in the share price the next day.
Here's a look at CareDx's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.11</td>
<td>-0.07</td>
<td>-0.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>61.76M</td>
<td>80.70M</td>
<td>81.66M</td>
<td>82.62M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>70.30M</td>
<td>77.26M</td>
<td>82.38M</td>
<td>79.36M</td>
</tr>
</tbody>
</table>

To track all earnings releases for CareDx <a href="https://www.benzinga.com/quote/CDNA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CareDx: Q3 Earnings Insights

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.39) by 53.85 percent. This is a 200 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $67.19 million which beat the analyst consensus estimate of $53.14 million by 26.44 percent. This is a 15.33 percent decrease over sales of $79.36 million the same period last year.

CareDx Q3 Adj EPS $(0.18) Beats $(0.39) Estimate, Sales $67.19M Beat $53.14M Estimate

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. Here's what investors need to know before the announcement.
Analysts estimate that CareDx will report an earnings per share (EPS) of $-0.39. 
CareDx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 11.23% drop in the share price the next day.
Here's a look at CareDx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.11</td>
<td>-0.07</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.23%</td>
<td>-2.68%</td>
<td>14.34%</td>
<td>-14.47%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699376543_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of CareDx were trading at $6.48 as of November 06. Over the last 52-week period, shares are down 54.58%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CDNA/earnings">To track all earnings releases for CareDx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares rose 62.0% to $1.29 during Thursday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) stock increased by 17.04% to $3.09. The market value of their outstanding shares is at $171.7 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares moved upwards by 14.78% to $6.21. The market value of their outstanding shares is at $336.3 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) stock rose 12.6% to $0.26. The company's market cap stands at $2.3 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares moved upwards by 12.54% to $0.25. The company's market cap stands at $14.9 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock rose 12.41% to $0.48. The market value of their outstanding shares is at $1.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) stock declined by 63.1% to $0.23 during Thursday's pre-market session. The market value of their outstanding shares is at $60.7 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) stock fell 25.86% to $0.75. The company's market cap stands at $20.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock fell 24.46% to $3.83. The market value of their outstanding shares is at $49.8 million. </li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares fell 13.13% to $66.2. The company's market cap stands at $25.1 billion. The company's, Q3 earnings came out today. </li>
<li>Sonendo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONX#NYSE">SONX</a>) shares fell 12.42% to $0.23. The market value of their outstanding shares is at $12.2 million. </li>
<li>Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) shares decreased by 11.92% to $20.25. The company's market cap stands at $3.3 billion. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

AKAN

ATXI

CLLS

DRIO

GNPX

MRNA

NVST

OTLK

PBLA

SONX

<h3>Gainers</h3>
<ul>
<li>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) stock moved upwards by 11.1% to $10.68 during Wednesday's after-market session. The market value of their outstanding shares is at $606.6 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) stock moved upwards by 10.9% to $6.0. This security traded at a volume of 120.8K shares come close, making up 15.6% of its average volume over the last 100 days. The company's market cap stands at $325.0 million. </li>
<li>Procaps Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) shares increased by 10.14% to $3.04. The market value of their outstanding shares is at $342.9 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares increased by 9.17% to $2.26. At the close, Community Health Sys's trading volume reached 108.0K shares. This is 7.6% of its average volume over the last 100 days. The company's market cap stands at $309.1 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares increased by 9.09% to $1.32. The company's market cap stands at $3.8 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock rose 9.07% to $1.45. The market value of their outstanding shares is at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) stock declined by 18.3% to $14.5 during Wednesday's after-market session. Trading volume for this security closed at 112.8K, accounting for 7.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $943.6 million. As per the news, the Q3 earnings report came out today. </li>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) stock declined by 17.72% to $19.0. The company's market cap stands at $680.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) stock fell 11.71% to $38.25. The market value of their outstanding shares is at $1.8 billion. The company's, Q3 earnings came out today. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) shares declined by 11.62% to $0.75. Today's trading volume for this security ended up closing at 101.4K shares, which is 72.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $8.4 million. </li>
<li>Impel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMPL#NASDAQ">IMPL</a>) stock decreased by 10.5% to $0.26. The market value of their outstanding shares is at $6.1 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares fell 10.01% to $0.21. The company's market cap stands at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

ARTL

CCRN

HSCS

IMPL

PHAT

PROC

SIEN

STAA

12 Health Care Stocks Moving In Wednesday's After-Market Session

CareDx Q4 2023 Earnings Preview

CareDx Non-GAAP EPS of -$0.17 beats by $0.10, revenue of $65.6M beats by $1.54M

CareDx (CDNA) has provided an announcement. CareDx, Inc. has released an updated corporate presentation, providing the latest insights into the com...

CareDx Unveils Updated Financial Health and Strategy Presentation

CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript

H.C. Wainwright analyst Yi Chen has reiterated their neutral stance on CDNA stock, giving a Hold rating yesterday. Yi Chen has given his Hold ratin...

Balancing Growth Prospects Against Financial Challenges: A Hold Rating for CareDx

BTIG analyst Mark Massaro has reiterated their neutral stance on CDNA stock, giving a Hold rating on February 29. Mark Massaro has given his Hold r...

CareDx Hold Rating: Balancing Modest Growth Prospects with Operational Uncertainties

CareDx appoints Bryan Riggsbee to its board of directors

CareDx (CDNA) has provided an update. CareDx, Inc. recently bolstered its leadership by appointing seasoned finance professional R. Bryan Riggsbee ...

CareDx Enhances Board with Financial Expert Riggsbee

CareDx appoints John Hanna as president and CEO

CareDx (CDNA) just unveiled an announcement. CareDx, Inc. has announced that John W. Hanna will take the helm as President and CEO starting April 1...

CareDx Appoints John W. Hanna as New CEO and Board Member

Press Releases

CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium

CareDx Issues Statement in Patent Infringement Case

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

CareDx to Participate in the Raymond James & Associates' 45th Annual Institutional Investors Conference

CareDx Announces Fourth Quarter and Full Year 2023 Financial Results

CareDx Appoints Bryan Riggsbee to Its Board of Directors

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting